Abstract 4554: Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial2024 · 12 citations
2. 2Abstract 7191: Targeting IGF1R/INSR pathway with approved ALK inhibitors inhibits AKT signaling and overcomes proteasome inhibitor resistance in multiple myeloma2024
3. 3Abstract 7542: <i>In vitro</i> and <i>in vivo</i> evaluation of bortezomib using the 5TGM1 cell line and a syngeneic mouse model of multiple myeloma2026
4. 4Abstract 420: Targeting proliferating cell nuclear antigen via a miRNA-CSC axis as a new therapeutic approach in multiple myeloma.2026
5. 5Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma2025 · 1 citations